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ABSTRACT 23 
Hepatitis C virus (HCV) enters cells via interactions with several host factors, a key 24 
one being that between the viral E2 envelope glycoprotein and the CD81 receptor. We 25 
previously identified the E2 tryptophan 420 (W420) as an essential CD81-binding 26 
residue. However, the importance of W420 in the context of the native virion is 27 
unknown as these earlier studies predate the infectious HCV cell-culture (HCVcc) 28 
system. Here, we introduced four separate mutations (F, Y, A or R) at position 420 29 
within the infectious JFH-1 HCVcc genome and characterized their effects on the 30 
viral cycle.  Whilst all mutations reduced E2-CD81 binding, only two (W420A and 31 
W420R) reduced HCVcc infectivity. Further analyses of mutants with hydrophobic 32 
residues (F or Y) found that interactions with receptors SR-BI as well as CD81 were 33 
modulated which in-turn determined the viral uptake route. Both mutant viruses were 34 
significantly less dependent on SR-BI, and its lipid-transfer activity, for virus entry. 35 
Furthermore, they were resistant to the drug erlotinib that targets EGFR (a host co-36 
factor for HCV entry) and also blocks SR-BI dependent HDL-mediated enhancement 37 
of virus entry. Together, our data indicate a model where alteration at position 420 38 
causes a subtle change in E2 conformation that prevents interaction with SR-BI and 39 
increases accessibility to the CD81 binding site in-turn favoring a particular 40 
internalization route. They further show that a hydrophobic residue with a strong 41 
preference for tryptophan at position 420 is important, both functionally and 42 
structurally, to provide an additional hydrophobic anchor to stabilize the E2-CD81 43 
interaction. 44 
IMPORTANCE 45 
Hepatitis C virus (HCV) is a leading cause of liver disease causing up to 500000 46 
deaths annually. The first step in the viral life-cycle is the entry process. This study 47 
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investigates the role of a highly conserved residue, tryptophan 420 of the viral 48 
glycoprotein E2 in this process. We analyzed the effect of changing this residue in the 49 
virus and confirmed that this region is important for binding to the CD81 receptor. 50 
Furthermore, alteration of this residue modulated the interaction with the SR-BI 51 
receptor and changes to these key interactions were found to affect the virus 52 
internalization route involving the host co-factor, EGFR. Our results also show that 53 
the nature of the amino acid at this position is important functionally and structurally 54 
to provide an anchor-point to stabilize the E2-CD81 interaction. 55 
 56 
INTRODUCTION 57 
HCV is a positive-strand RNA virus belonging to the Hepacivirus genus within the 58 
Flaviviridae family (1).The viral genome comprises a single open reading frame 59 
(ORF), encoding structural and non-structural (NS) proteins, flanked by two 60 
untranslated regions (UTRs) at the 5' and 3' ends. The large polyprotein of 61 
approximately 3000 amino acids [aa] is cleaved by cellular and viral proteases into 10 62 
different proteins: core, E1, E2, p7, NS2, NS3, NS4A, NS4B, NS5A, and NS5B 63 
(2).The structural proteins include core, which forms the viral nucleocapsid and the 64 
envelope glycoproteins E1 and E2 that mediate early cell entry events (3). NS2 and p7 65 
(a viroporin) play crucial roles in virus assembly/egress (4-6) and the remaining non-66 
structural proteins NS3, NS4A, NS4B, NS5A, and NS5B form replication complexes, 67 
which synthesize both plus and minus-strand viral RNAs (7). HCV is classified into 68 
seven major genetic groups and further subdivided into numerous subtypes (1, 8). 69 
This genetic variability is caused by the error-prone nature of the RNA-dependent 70 
RNA polymerase (NS5B), amplified by the high viral production rate (9) and further 71 
accelerated by the selective pressure exerted by the host immune response (10). 72 
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 73 
The viral particle consists of a nucleocapsid encasing the viral RNA, surrounded by a 74 
lipidic cell-derived envelope in which the glycoproteins E1 and E2 are embedded. 75 
Numerous reports have shown that both serum- and cell-culture-derived HCV 76 
(HCVcc) are tightly associated with low density lipoproteins (LDLs) and very low 77 
density lipoproteins (VLDLs) to form a hybrid particle called a lipoviroparticle (LVP) 78 
(11, 12). In vivo, these associations are believed to protect HCV from the humoral 79 
immune response by shielding the glycoproteins from circulating neutralizing 80 
antibodies (nAbs) (3). HCVcc studies have also shown that the major VLDL 81 
component, apoE, functions in the viral entry process (13). HCV entry into 82 
hepatocytes is a multi-step process involving a series of interactions between the virus 83 
particles and several cellular molecules. Initial attachment of HCV to the cell surface 84 
most likely occurs via interactions between virion-associated apoE with low-density-85 
lipoprotein receptor (LDLR) and with glycosaminoglycans (GAGs), present on 86 
heparan sulfate proteoglycans (HSPGs) (14-18). To gain entry into the cell, HCV 87 
depends on several cellular molecules: scavenger receptor BI (SR-BI) (19); 88 
tetraspanin CD81 (20); tight junction proteins claudin-1 (21) and occludin (22); 89 
epidermal growth factor receptor (EGFR) (23) and its signal transducer Harvey rat 90 
sarcoma viral oncogene homolog (HRas) (24); Niemann–Pick C1-like cholesterol 91 
receptor (NPC1L1) (25) and transferrin receptor 1 (26). The interaction of HCV 92 
particles with the cell leads to the internalization of particles through clathrin-93 
mediated endocytosis (27, 28) and their subsequent fusion at low pH with the 94 
membranes of early endosomes (29). Only two of these host cell molecules, CD81 95 
and SR-BI have been reported to interact directly with the HCV envelope 96 
glycoproteins (19, 20). SR-BI mediates binding of E2 through an interaction that 97 
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involves the hypervariable region 1 (HVR1), a 27 amino acid segment located at the 98 
N-terminus of the HCV E2 glycoprotein. It is believed that HVR1 masks or induces 99 
masking of the E2-CD81 binding site and that the E2-SR-B1 interaction facilitates 100 
conformational changes within the glycoproteins that cause exposure of the CD81 101 
binding site (30). CD81 has been demonstrated to have a major role in HCV entry and 102 
is the best characterized of the cellular entry factors to date. Numerous studies have 103 
identified E2 regions and residues that are potentially involved in CD81 interaction 104 
based on the characterization of neutralizing antibodies, mutagenesis studies, and 105 
structural data (31). However, most of these studies used soluble E2 or HCV 106 
pseudoparticle (HCVpp)-derived E2 in which the conformation of E2 is slightly 107 
different from the envelope glycoproteins in native HCV particles (32). Therefore, it 108 
remains unclear which E2 residues or sequences are genuinely involved in the 109 
interaction of virus particles with CD81. Prior to the availability of the HCVcc system 110 
we identified several residues required for E2-CD81 binding by alanine mutagenesis 111 
(33). One of these residues, W420, was located within the highly conserved E2 112 
epitope I, comprising residues 412-423. We also showed that the mouse monoclonal 113 
antibody (mAb) AP33, which inhibits the E2-CD81 interaction, bound to this epitope 114 
and specifically recognized residues L413, N415, G418 and W420 (33, 34). Analysis 115 
of amino acid variation within the AP33 epitope shows that W420 is 99.9% conserved 116 
(35), which suggests that it is functionally or structurally important. Epitope mapping 117 
has shown it to be a contact residue for several broadly neutralizing antibodies, 118 
including AP33 (reviewed in (36)). More recently this has been confirmed by 119 
structural analysis, which reveals how extensively this residue is bound by the 120 
neutralizing antibodies that recognize this epitope (35, 37-40). 121 
 122 
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To further investigate the role of W420 in CD81 binding and virus infection, we 123 
substituted this residue with phenylalanine, tyrosine, alanine or arginine in the 124 
genotype 2a HCVcc JFH-1 background. We then characterized the mutant viruses by 125 
testing their viral replication levels, cellular receptor interactions and sensitivity to 126 
neutralizing antibodies. We confirmed that W420 is important for CD81 binding 127 
during virus entry and interestingly also modulates virion interaction with receptor 128 
molecules SR-BI and EGFR. Together, our results suggest that the tryptophan as a 129 
large hydrophobic residue functions in conjunction with other CD81-binding regions 130 
to provide an additional anchor-point to stabilize the E2-CD81 interaction. 131 
 132 
MATERIAL AND METHODS 133 
Cells. Human epithelial kidney cells (HEK)-293T (ATCC CRL-1573), human 134 
hepatoma Huh-7 (41) and Huh7-J20 (42) were propagated in Dulbecco’s modified 135 
essential medium supplemented with penicillin/streptomycin, non-essential amino 136 
acids and 10% fetal calf serum (DMEM). CHO-K1 cells were propagated in HAM F-137 
12 medium (Life Technologies) supplemented as above. Stable cell-lines CHO-hSR-138 
BI or CHO-hSR-BI-GFP were generated by cloning sequences encoding the human 139 
SR-BI or SR-BI-EGFP fusion protein into the retrovirus transfer vector pQCXIP (BD 140 
Biosciences). These plasmids were co-transfected with constructs expressing MLV 141 
gag-pol and vesicular stomatitis virus (VSV) G glycoprotein into HEK-293T cells to 142 
generate VSV-G pseudoparticles (VSVpp). CHO-K1 cells were transduced with 143 
VSVpp carrying the gene encoding human SR-BI or SR-BI-EGFP and transduced 144 
cells were selected in medium containing 4 μg/ml puromycin.  145 
 146 
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Antibodies. The anti-E2 rodent mAbs AP33, 3/11 and human mAb (HmAb) CBH-5 147 
have been described previously (43-46). The anti-E2 mAbs CBH-5, 3/11, and the anti-148 
NS5A mAb 9E10 (47), were kindly provided by S. Foung, J. McKeating and C. M. 149 
Rice, respectively. The murine leukemia virus (MLV) gag-specific mAb was obtained 150 
from rat hybridoma cells (ATCC CRL-1912). The anti-core mAb C7-50, and the anti-151 
CD81 mAb JS-81 were obtained from Bioreagents and BD Biosciences, respectively. 152 
The anti-Flag M2 mAb was obtained from Sigma-Aldrich. A derivative of anti-SR-BI 153 
human mAb151 described previously (48) was generated in CHO-K1 cells. Briefly, 154 
the variable heavy (vH) and variable light (vL) chain encoding sequences of mAb151 155 
were cloned into mouse IgG1 expression vectors pFUSEss-CHIg-mg1 and 156 
pFUSE2ss-CLIg-mk (InvivoGen, CA, USA), respectively. Following co-transfection 157 
of these plasmids into CHO-K1 cells, a clone stably secreting the human-mouse 158 
chimeric IgG (called mAb151-NP1) was selected and expanded. MAb151-NP1 159 
secreted into the medium was purified using protein G-sepharose affinity 160 
chromatography and confirmed to react specifically to human SR-BI. Cell-surface 161 
expression of SR-BI was measured by incubating cells with anti-SR-BI mAb151-NP1 162 
or an isotype IgG1 control, followed by an anti-mouse phycoerythin (PE)-conjugated 163 
secondary antibody. The cells were analyzed by flow cytometry on a FACScalibur 164 
with CellQuest Pro software (BD biosciences).  165 
 166 
Plasmid constructs and mutagenesis. The plasmid pUC-JFH-1 carries the full-167 
length cDNA of the genotype 2a HCV strain JFH-1. The plasmid pUC-GND JFH-1 is 168 
identical except for the GND mutation in the viral NS5B RNA polymerase (49).  The 169 
plasmids used to generate HCV pseudoparticles (HCVpp) containing the strain JFH-1 170 
envelope glycoproteins have been described previously (50). Site-directed 171 
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mutagenesis was carried out by using a QuikChange-XL-II kit (Agilent Technologies) 172 
according to the manufacturer’s instructions to introduce amino acid substitutions at 173 
the target sites in E2. Briefly, the amino acid substitutions W420F, W420Y, W420A, 174 
W420R and W420V in the E2-coding region were individually introduced into the 175 
plasmid pUC-JFH-1 using appropriate primers (the sequences of which are available 176 
upon request). The presence of the desired mutations in the resulting clones was 177 
confirmed by sequencing the DNA fragments spanning the mutation site and then 178 
these fragments were subcloned back into pUC-JFH-1 and the HCVpp E1E2 179 
expression vector. 180 
 181 
Determination of virus infectivity and RNA replication. Infectious viruses were 182 
generated by electroporation of viral RNA into Huh7 cells as previously described 183 
(49). Infectious virus titers in the cell medium were determined by infecting Huh7 184 
cells with serially diluted inoculum followed by immunostaining for the NS5A viral 185 
protein in a focus forming unit (FFU) assay as described previously (51). The level of 186 
virus infectivity and intracellular RNA replication was determined by infecting the 187 
reporter cell line Huh7-J20 and measuring the secreted alkaline phosphatase (SEAP) 188 
activity in the culture medium at indicated times post-infection as described 189 
previously (42). To monitor virus infectivity during serial passaging, Huh7 cells 190 
electroporated with the viral RNA or inoculated with infectious virus were passaged 191 
in T80 flasks containing DMEM. At each passage the cell culture supernatants were 192 
harvested, and the released virus infectivity was determined by FFU assay. To 193 
determine the replication of each mutant virus, 2 x 106 Huh7-J20 cells were 194 
electroporated with 10 μg of viral RNA and resuspended in 4 ml of DMEM. Aliquots 195 
of 0.5 ml were then seeded into triplicate wells of a 24-well plate. Following 196 
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incubation at 37°C for 72 h, the virus infectivity/replication levels and infectious virus 197 
yields in cell culture supernatants were determined by SEAP and FFU assay, 198 
respectively. Cell-associated virus was obtained essentially as described previously 199 
(52). Briefly, 3 x 106 Huh-7 cells were electroporated with 10 μg of viral RNA, 200 
resuspended in 15 ml of DMEM, and seeded into 90-mm culture dishes. Cells were 201 
harvested at 72 h postelectroporation, washed in DMEM, resuspended in 0.8 ml 202 
DMEM, and freeze-thawed three times. The samples were centrifuged to remove cell 203 
debris, and the supernatant was assayed by FFU assay to determine virus infectivity.  204 
 205 
Western blot analysis. Western blot analysis was performed as described previously 206 
(43), with some modifications. To detect intracellular antigens, cultured cells were 207 
washed once in phosphate-buffered saline (PBS) and lysed directly in SDS-PAGE 208 
sample loading buffer (200 mM Tris-HCl, pH 6.7; 0.5% SDS; β-mercaptoethanol; 209 
10% glycerol). Lysates were homogenized by passing through a 22-gauge needle five 210 
times before use. To obtain extracellular virus, 10 ml of culture medium from 211 
electroporated cells was harvested, filtered, and overlaid onto 1 ml of a 20% (wt/vol) 212 
sucrose cushion made with PBS and centrifuged at 25,000 rpm for 4 h in a Sorvall 213 
Discovery 90SE ultracentrifuge. The pellets were then lysed directly in 50 μl of SDS-214 
PAGE sample loading buffer and stored at -20°C until use. The proteins in 20 μl of 215 
sample were resolved by 12.5% SDS-PAGE and transferred onto nitrocellulose 216 
membranes (Hybond-ECL; Amersham).  217 
 218 
Identification of reversion mutations. Total RNA was prepared from infected cells 219 
using the RNeasy kit (Qiagen), and the HCV RNA was converted to first-strand DNA 220 
by using a Superscript III first-strand synthesis kit (Invitrogen) with the primer 5′-221 
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TTGCGAGTGCCCCGGGA-3′. After digestion with 1 U of RNase H (Invitrogen) for 222 
20 min at 37°C, one-quarter of the RT reaction was amplified with appropriate 223 
primers to yield four fragments of HCV cDNA (nucleotides [nt] 322 to 930, 538 to 224 
3038, 2544 to 5542, and 5412 to 7890) covering the core to NS5A regions of the viral 225 
genome. The PCR products were gel purified and used directly for nucleotide 226 
sequencing. 227 
 228 
HCVpp genesis, infection, and analysis by immunoblotting. HCVpp were 229 
generated by transfection of HEK-293T cells with plasmids expressing HCV E1E2, 230 
MLV Gag-pol and the MLV transfer vector expressing a firefly luciferase reporter. 231 
The medium containing HCVpp was collected, filtered through 0.45-µm-pore-size 232 
membrane and used to infect Huh7 cells as described previously (53). Three days 233 
after infection, the cells were lysed and their luciferase activity measured using a 234 
Bright-Glo luciferase assay system (Promega).  For protein analysis, HCVpp-235 
containing medium was pelleted through a 20% sucrose cushion (wt/vol) in PBS at 236 
100,000 x g for 2 h. The pellets were resuspended in SDS-PAGE sample loading 237 
buffer and analyzed by SDS-PAGE followed by immunoblotting for HCV E2 and 238 
MLV gag. 239 
 240 
GNA capture and CD81 binding assay. The enzyme-linked immunosorbent assay 241 
(ELISA) to detect mAb binding to E2 glycoprotein was performed essentially as 242 
described previously (54). Briefly, HEK-293T cells were cotransfected with E1E2 243 
expression plasmids, and the expressed glycoproteins present in clarified lysates of 244 
these cells were captured onto GNA (Galanthus nivalis agglutinin)-coated Immulon II 245 
enzyme immunoassay (EIA) plates (Thermolabsystems). Bound glycoproteins were 246 
 11
detected using biotinylated anti-E2 mAbs, followed by Streptavidin-horseradish 247 
peroxidase (Sigma-Aldrich) and TMB (3,3′,5,5′-tetramethylbenzidine; Sigma-248 
Aldrich) substrate. Absorbance values were determined at 450 nm. The E2-CD81 249 
binding assay was essentially performed as above. Briefly, E1E2 from cell lysates was 250 
captured onto an ELISA plate coated with GNA, the wells washed and an insect cell-251 
expressed FLAG-tagged human soluble CD81-LEL (sCD81-LEL) was added. The 252 
bound CD81 was detected using anti-FLAG antibody, followed by anti-mouse-253 
horseradish peroxidase as described above.  254 
 255 
HCVcc neutralization assays. Inhibition assays were performed in Huh7-J20 cells, 256 
and virus infectivity levels were determined by SEAP reporter assay, as described 257 
previously (42). Briefly, cells were seeded at a density of 4 x 103 per well in a 96-well 258 
plate and incubated at 37oC overnight prior to infection. For anti-E2 antibody 259 
neutralization assays, virus was preincubated at 37°C for 1 h with the appropriate 260 
antibody prior to infecting cells at m.o.i 0.1. To test neutralization by sCD81-LEL, 261 
virus was preincubated at 37°C for 1 h with purified His-tagged sCD81-LEL 262 
expressed in E.coli as described previously (55) prior to infecting cells at m.o.i 0.1. To 263 
test neutralization by anti-receptor antibodies, cells were preincubated with 264 
appropriate antibodies for 1 h at 37°C prior to infection at m.o.i 0.1. At 3 h 265 
postinfection, the inoculum was replaced with fresh DMEM and incubated for 48 h.  266 
 267 
HCVcc dose-response assays. BLT-4, erlotinib and sunitinib were obtained from 268 
Sigma-aldrich. The assay was performed similarly to the neutralization assay 269 
described above except cells were pretreated with inhibitor for 1 h at 37°C prior to 270 
infection at m.o.i 0.1 for 3h, the inoculum and inhibitor was removed, cells were 271 
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washed and fresh media added. After 72 h incubation, the SEAP activity in the media 272 
was measured. Cell viability assays were performed in Huh7-J20 cells seeded at 4 x 273 
103 per well in a 96-well plate and incubated at 37oC overnight prior to treatment. 274 
Cells were treated with inhibitor for 4h at 37°C, washed and fresh media added. 275 
Following 72h incubation, media was removed and cells were incubated in 10% 276 
WST-1 reagent (Roche) and absorbance at 440nm measured.  277 
 278 
RESULTS 279 
Effects of E2 Mutations on Virus Replication. To assess the role of E2 residue 280 
W420 in virus infection, we generated HCVcc mutants containing the amino acid 281 
substitutions W420A, W420R, W420F and W420Y. Alanine, with its small, non-282 
polar side chain is most commonly used for site-directed mutagenesis, but it is more 283 
informative to introduce residues that cover a wider range of physico-chemical 284 
properties. In this case, replacing tryptophan with the aromatic residues phenylalanine 285 
or tyrosine is a relatively conservative change.  Substitution by arginine, a positively 286 
charged polar residue, is a drastic change, but we decided to include it because this 287 
mutation is found in one of 2,161 naturally occurring HCV E2 sequences (35). To 288 
study the effect of these mutations on virus replication, Huh7-J20 cells were 289 
electroporated with JFH-1WT, JFH-1W420F, JFH-1W420Y, JFH-1W420A or JFH-1W420R 290 
RNA and after 72 h the supernatant was harvested for FFU and SEAP assay. All of 291 
the mutants showed SEAP activities similar to that of JFH-1WT (Fig. 1a). Cells 292 
electroporated with the replication-deficient JFH-1GND RNA and replication-293 
competent but assembly-deficient JFH-1ΔE1E2 served as controls in this experiment. 294 
These results indicate that the E2 mutations do not alter intracellular HCV RNA 295 
replication. Similar levels of viral proteins core, E2 and NS5A were detected in all the 296 
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cell lysates, confirming that these mutations do not affect genome or protein synthesis 297 
(Fig. 1c).  In contrast, major differences were observed in the titer of infectious virus 298 
released into the cell medium (Fig.1b).  JFH-1W420F and JFH-1W420Y viruses showed 299 
comparable peak titers to JFH-1WT, whereas the infectivity of the JFH-1W420A and 300 
JFH-1W420R viruses was reduced by ~1 log10 and ~4 log10, respectively. A similar 301 
infectivity profile was obtained using intracellular virus (recovered from cells lysed 302 
by freeze-thawing), indicating that the defect in JFH-1W420A and JFH-1W420R 303 
infectivity is not due to reduced virion secretion (Fig. 1b). To determine whether the 304 
W420 mutants were producing non-infectious viral particles, culture medium 305 
harvested 72 h post-electroporation was concentrated and probed for the presence of 306 
core protein by immunoblotting, and also tested for infectivity. We found that all the 307 
mutants secreted levels of extracellular core protein similar to JFH-1WT, whereas the 308 
infectivity of JFH-1W420A and JFH-1W420R was very much reduced (Fig. 1c, pelleted), 309 
which means that these mutations alter the specific infectivity of particles, with little 310 
or no effect on virus assembly and secretion.  311 
 312 
Reversion of E2 mutants during prolonged culture. To determine whether the 313 
infectivity of the JFH-1W420A and JFH-1W420R mutants could be rescued by 314 
compensatory mutations, cells electroporated with JFH-1W420R RNA or infected with 315 
JFH-1W420A virus were serially passaged. The level of infectious virus released into 316 
the culture medium was monitored throughout each passaging experiment. A 317 
progressive increase in extracellular virus release was observed in both experiments 318 
that eventually achieved peak titers similar to those expected for JFH-1WT (data not 319 
shown). To identify the mutation(s) responsible for this increased infectivity, total 320 
RNAs were prepared from cells infected with virus collected from the final passage 321 
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and the core to NS5A encoding regions of the HCV genome were sequenced by RT-322 
PCR. Interestingly, the sequencing revealed that the JFH-1W420R virus had reverted 323 
back to the wild type tryptophan residue by a single nucleotide change (CGG to TGG) 324 
which emphasizes the functional importance of W420. The passaged JFH-1W420A also 325 
contained a single nucleotide change (GCG to GTG) thereby converting the original 326 
alanine substitution to a valine residue. To determine if this valine substitution was 327 
indeed responsible for the improved infectivity of JFH-1W420A seen during passaging, 328 
we engineered this change into the original JFH-1WT genome and analyzed infectious 329 
virus production at 72 h post-electroporation. As shown in Fig. 1d the JFH-1W420V 330 
mutant displayed cell-free infectivity comparable to JFH-1WT, suggesting that the 331 
JFH-1A420V change functions as a reversion mutation.  332 
 333 
Infectivity Profiling in the HCVpp System 334 
We previously showed that a W420A mutation in the HCV genotype 1a strain H77 E2 335 
abolished HCVpp infection (33). However, the results presented here show that the 336 
same mutation in the strain JFH-1 HCVcc system only reduces infection 10-fold. To 337 
resolve this discrepancy, we assessed the infectivity of the JFH-1 E2 W420 mutants in 338 
the HCVpp system. In contrast to the results in HCVcc, we found that W420Y 339 
retained 5% infectivity compared to wild type and the rest of the W420 mutants were 340 
non-infectious in the HCVpp system (Fig. 2a). The HCVpp infectivity data do not 341 
correspond to the E2-CD81 binding data (see below and Fig. 5a), as the W420F 342 
mutant retained CD81 binding activity but was not infectious. Thus, the reasons for 343 
the lower infectivity of the mutant HCVpps are not clear. Using E2 GNA-capture 344 
ELISA, we confirmed that the wild type and the mutant E2 glycoproteins were 345 
expressed intracellularly in comparable quantities (data not shown). However, we 346 
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consistently found less incorporation of E2 mutants W420A, W420V and W420R into 347 
the secreted HCVpps (Fig. 2b). The level of W420R E2 was extremely low while the 348 
levels of W420A and W420V mutant E2 were clearly reduced relative to wild type. In 349 
contrast, the incorporation of W420F and W420Y E2 into HCVpp was higher than 350 
that of the wild type protein even though the HCVpps displayed reduced or no 351 
infectivity in Huh7 cells (Fig. 2). The lack of infectivity of the W420A, V and R 352 
HCVpp mutants is likely explained by the reduced E2 incorporation into the 353 
pseudoparticles.  354 
 355 
E2 mutations alter sensitivity to neutralizing antibodies. We assessed the 356 
reactivity of three broadly neutralizing monoclonal antibodies (mAbs), AP33, 3/11 357 
and CBH-5 to each mutant E2 by GNA capture ELISA. Both AP33 and 3/11 bind to 358 
distinct but overlapping epitopes within the highly conserved region of E2 spanning 359 
residues 412 to 423 (QLINTNGSWHIN), with W420 being a critical contact residue 360 
for both antibodies (34). Recent structural data however, has revealed that this region 361 
is flexible. AP33 binds to a β-hairpin structure, in contrast, 3/11 recognizes an open 362 
conformation of this region (37-39). HmAb CBH-5 binds to an epitope within the 363 
CD81 binding region; substitution of E2 residues G523, P525, G530, D535 and N540 364 
with alanine was reported to ablate CBH-5 binding, whereas mutation at W420 did 365 
not reduce binding by >50% (56). Further studies have shown that this antibody maps 366 
to immunodomain B and directly competes with CD81 for binding to E2 (44, 57, 58). 367 
A panel of HEK-293T cell lysates containing wild type or mutant HCV E1E2 was 368 
first tested for reactivity to an anti-E2 mAb DAO5 that recognizes a linear epitope 369 
spanning aa 532-540 (Vasiliauskaite et al. manuscript in preparation). As expected all 370 
lysates had similar reactivity to this mAb indicating that the proteins were expressed 371 
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in equivalent quantities (Fig. 3a). All W420 mutants showed undetectable binding 372 
levels to mAb AP33 in the ELISA assay, confirming that this is a critical residue for 373 
mAb AP33-E2 interaction (Fig. 3b). In contrast, while mutants W420A, V and R had 374 
no detectable binding to mAb 3/11, both aromatic substitution mutants W420F and 375 
W420Y retained 50% and 75% binding activity, respectively (Fig. 3c). The same 376 
panel of lysates was assessed for reactivity with HmAb CBH-5, which binds a 377 
conformational epitope within antigenic domain B of E2 (47). Although all W420 378 
mutants retained some level of binding activity, this correlated with the type of 379 
residue substituted. Both aromatic mutants (W420F and W420Y) retained 55% of 380 
binding activity compared to wild type, and both aliphatic residues (W420A and 381 
W420V) had similar binding, 36% and 41% of wild type respectively, while E2 382 
containing the positively charged W420R substitution only bound HmAb CBH-5 at 383 
20% of wild type activity. Subsequently, we investigated if these antibodies could 384 
neutralize W420 mutant virus, using the two aromatic mutants, which had similar 385 
levels of infectivity to wild type JFH-1. We found as predicted by the ELISA E2-386 
binding assay results that JFH-1W420Y was completely resistant to neutralization by 387 
mAb AP33. Surprisingly, JFH-1W420F showed a low but consistent level of inhibition 388 
at the highest concentrations of AP33 antibody tested (Fig. 4a) suggesting that this 389 
mutant can still bind mAb AP33 albeit at a level undetectable by ELISA assay. In 390 
contrast, we found that both mutants were neutralized by the 3/11 antibody that binds 391 
to E2412-423 in the open conformation. Although JFH-1W420F only binds mAb 3/11 to 392 
approximately 50% wild type levels, the inhibition profile did not show a 393 
corresponding change. Instead the mutant virus was inhibited similarly to wild type 394 
JFH-1 despite the reduction in binding affinity. Indeed the JFH-1W420Y mutant that 395 
retained 75% binding activity was found to be more sensitive to neutralization by 396 
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mAb 3/11 than wild type virus (Fig. 4b). We also tested neutralization using the CBH-397 
5 antibody that binds to an epitope within the CD81 binding region of E2 (Fig. 4c). 398 
Notably, both mutants were significantly more sensitive to inhibition with this 399 
antibody, with approximately 2000-fold less antibody required to inhibit the mutant 400 
viruses by 50% compared to wild type virus. The differences observed between the 401 
sensitivity of these mutant viruses to neutralization by these human and rodent 402 
antibodies versus their glycoprotein reactivity by ELISA indicates that the mutations 403 
may enhance the exposure of E2 on the virion. 404 
 405 
E2 mutations alter virus-receptor interactions. We used the panel of W420 E1E2 406 
lysates to examine the E2-CD81 binding reactivity of the intracellular viral 407 
glycoproteins to sCD81-LEL by ELISA. Remarkably, the majority of 420 mutants 408 
had no detectable binding to CD81, confirming the importance of this residue in the 409 
E2-CD81 interaction (Fig. 5a). The JFH-1W420F mutant however, could still bind to 410 
sCD81-LEL although binding was approximately 40% of wild type levels. To 411 
determine if the mutations have also reduced the affinity of E2 on the virion for the 412 
virus receptor CD81 we monitored neutralization of the JFH-1WT, JFH-1W420F and 413 
JFH-1W420Y viruses. Firstly, we used an anti-CD81 neutralizing antibody that binds to 414 
the CD81 receptor on the cell surface, and found that all viruses were similarly 415 
inhibited irrespective of their ability to bind sCD81-LEL in the ELISA assay (Fig. 416 
5b). Secondly, a competition assay using sCD81-LEL was performed. In this 417 
experiment we found that both W420 mutants were more sensitive to inhibition than 418 
JFH-1WT, with JFH-1W420F being the most sensitive (Fig. 5c). Even though no E2-419 
CD81 interaction was detected in the ELISA assay for the JFH-1W420Y, the inhibition 420 
profile with sCD81-LEL indicates that this mutant retains some affinity to CD81. This 421 
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parallels the earlier observations with mAb AP33 (Figs. 3b and 4a). Notably, the 422 
sensitivity of the mutant viruses to inhibition by sCD81-LEL (Fig. 5c) would not be 423 
predicted by their CD81-binding activity (Fig. 5a) although W420F that retained 40% 424 
binding activity to sCD81-LEL was the most sensitive to inhibition. This is in line 425 
with their greatly increased sensitivity to neutralization by HmAb CBH-5 (Fig. 4c), 426 
despite weaker binding to CBH-5 in ELISA (Fig. 3d). Together these data suggest 427 
increased exposure of CD81-binding sites on the 420 mutant virions. 428 
 429 
Having established that these mutations influence the HCV-CD81 interaction, we 430 
investigated their effects on SR-BI-dependent entry. SR-BI has been reported to have 431 
three distinct functions in HCV entry; modulating primary attachment via interaction 432 
with apolipoproteins such as ApoE on the HCV virion, an access function that 433 
depends on the lipid transfer activity of SR-BI and finally an infectivity enhancement 434 
function (30). Only the latter function is thought to require E2-SR-BI interaction. To 435 
investigate whether mutation at position 420 alters the interaction of the virion with 436 
the SR-BI receptor we monitored SR-BI neutralization of the JFH-1WT, JFH-1W420F 437 
and JFH-1W420Y viruses. The human-mouse anti-SR-BI mAb151-NP1 was expressed 438 
and purified, then specificity for human SR-BI was confirmed. The ability of anti-SR-439 
BI mAb151-NP1 to bind to CHO-KI cells expressing human SR-BI or human SR-440 
BI.EGFP was assessed by FACS analysis. Firstly, detection of GFP in the CHO-hSR-441 
BI-GFP cells confirmed expression of the SR-BI-EGFP fusion protein (Fig.6a).  As 442 
expected anti-SR-BI mAb151-NP1 bound to CHO-K1 cells expressing human SR-BI 443 
or human SR-BI.EGFP but not to the parental CHO-K1 cell-line confirming that the 444 
antibody specifically recognizes human SR-BI (Fig.6b, 6c, 6d). Naive Huh7-J20 cells 445 
were pre-incubated with varying concentrations of a neutralizing human-mouse anti-446 
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SR-BI mAb151-NP1 prior to infection with each virus. Interestingly, both mutants 447 
were considerably less sensitive than wild type to neutralization suggesting that these 448 
mutants are significantly less dependent on SR-BI for virus entry (Fig. 6e). However, 449 
the 420 mutants were inhibited by the highest concentrations of anti-SR-BI tested. 450 
Inhibitory SR-BI antibodies have been shown to inhibit both the primary attachment 451 
and lipid transfer activity functions (30). Therefore, to investigate which SR-BI 452 
function targeted by antibody treatment was responsible for the reduced sensitivity; 453 
we used the chemical inhibitor BLT-4 that blocks SR-BI lipid transfer activity (59). 454 
Huh7-J20 cells were preincubated with increasing concentrations of BLT-4 before 455 
infection with virus. In parallel, cell viability in the presence of BLT-4 was assessed 456 
and found to not be affected (Fig. 6g). JFH-1WT virus was sensitive to BLT-4 457 
treatment; in contrast the JFH-1W420F and JFH-1W420Y viruses were not inhibited even 458 
at the highest dose (Fig.6f). These data suggest that the W420 mutant viruses access 459 
the cells independently of SR-BI lipid transfer activity but can still use SR-BI for 460 
primary attachment. 461 
 462 
Studies have shown that high density lipoprotein (HDL) enhances HCVcc entry via 463 
SR-BI (60, 61). More recently Diao et al (2012) demonstrate that HDL enhancement 464 
can be inhibited by treatment with erlotinib that targets EGFR, a known host factor for 465 
HCV entry (62). This indicates that SR-BI and EGFR may use the same 466 
internalization pathway. Therefore we investigated whether mutation of W420 467 
affected EGFR-dependent entry. Naïve cells were pretreated with the EGFR kinase 468 
inhibitor erlotinib prior to infection with virus. As expected JFH-1WT virus was 469 
sensitive to erlotinib in a dose-dependent manner with an IC50 of 0.244μM, which is 470 
in agreement with the range observed previously (Fig. 7a) (23, 62). In comparison the 471 
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JFH-1W420F and JFH-1W420Y viruses were markedly less sensitive to erlotinib treatment. 472 
In parallel, cell viability was assessed and erlotinib treatment was found to have no 473 
effect (Fig.7b). Erlotinib targets the tyrosine kinase domain of EGFR; however 474 
previous studies also indicate a role for the ligand-binding domain of EGFR in HCV 475 
entry. Although the previous studies agree that EGFR ligands such as EGF promote 476 
HCV infection, the data is conflicting with regard to the effect of an EGFR 477 
neutralizing antibody that prevents ligand interaction (23, 62). We determined the 478 
response of JFH-1WT, JFH-1W420F or JFH-1W420Y to incubation in the presence of 479 
EGFR antibody (LA-1) (Fig.7c). In agreement with Diao and co-workers we found 480 
that antibody treatment did not block JFH-1WT HCVcc infection. Moreover, there was 481 
no difference between the wildtype virus and the W420 mutants. The main target of 482 
erlotinib is EGFR however; Neveu et al recently reported that erlotinib also inhibits 483 
cyclin G-associated kinase (GAK) during HCV entry (63). GAK is a regulator of 484 
clathrin-mediated endocytosis that recruits clathrin and AP2 to the plasma membrane. 485 
GAK has been shown to regulate EGFR internalization and promote EGF uptake (64). 486 
Therefore erlotinib treatment targets two steps of the EGFR pathway. The resistance 487 
to erlotinib inhibition indicates that JFH-1W420F and JFH-1W420Y do not require the 488 
EGFR/GAK route for entry. The host cell kinase AP-2-associated protein kinase 1 489 
(AAK1) is a second regulator of AP-2 clathrin-mediated endocytosis. AAK1 was also 490 
shown to regulate EGFR-mediated HCV entry (63). Therefore we used sunitinib, a 491 
kinase inhibitor that targets AAK1 to investigate if the W420 mutants require AAK1.  492 
Huh7-J20 cells were pretreated with increasing concentrations of sunitinib prior to 493 
infection with virus. We found that JFH-1WT, JFH-1W420F and JFH-1W420Y viruses were 494 
inhibited by sunitinib in a dose-dependent manner (Fig.7d). Interestingly, at the 495 
highest concentrations tested the mutants were more sensitive to sunitinib inhibition 496 
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than JFH-1WT virus indicating that the mutants were more dependent on this entry 497 
route (Fig.7e). Sunitinib treatment was found to only affect cell viability at the highest 498 
concentration tested (Fig.7f).  499 
 500 
DISCUSSION 501 
We investigated the role of the highly conserved tryptophan at aa position 420 within 502 
the AP33 epitope of the E2 glycoprotein by substituting this residue in the full length 503 
viral genome with phenylalanine, tyrosine, alanine, arginine and valine. The 504 
phenotypes of the E2 mutants in this study highlight the importance of tryptophan 420 505 
during virus infection. None of the substitutions at position 420 had an effect on viral 506 
replication levels, but overall viral titers of the JFH-1W420A and JFH-1W420R viruses 507 
were significantly decreased. Analysis of the amount of HCV core protein present in 508 
the medium indicates that there is no effect on virus assembly and secretion. The 509 
decrease in viral titers is apparent in the FFU/ml assay, which requires infection of 510 
naïve cells, and therefore reveals a defect in the entry step of the viral lifecycle.  511 
 512 
It is remarkable that the only mutation at this position detected in one out of 2161 513 
naturally occurring HCV sequences was W420R, particularly as our results indicate 514 
that this virus is very disabled. In addition, the fact that upon serial passaging, the 515 
JFH-1W420R virus reverted to the wild type sequence is strong evidence that W420 is 516 
important for function. However, these mutations were only assessed in a JFH-1 517 
background, therefore it is possible that other compensatory mutations were present in 518 
the natural variant that improved viral fitness. In terms of amino acid properties, 519 
phenylalanine and tyrosine are the most conservative mutations to replace tryptophan. 520 
Indeed, the unaltered infectivity of the JFH-1W420F and JFH-1W420Y mutants suggest 521 
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that other aromatic residues can replace the tryptophan residue at this position. 522 
Furthermore, our results with JFH-1W420A and JFH-1W420V also demonstrate that 523 
smaller residues can substitute for the tryptophan, albeit less efficiently in the case of 524 
alanine. Indeed considering our mutagenesis data in the HCVcc system it is somewhat 525 
surprising that W420 is so strictly conserved in nature. In contrast, the data from the 526 
HCVpp system clearly show that tryptophan is essential at this position as all 527 
substitutions severely reduced infectivity. Our data also suggest a requirement for 528 
W420 for efficient assembly of HCVpps, as W420A, V and R HCVpp contained low 529 
levels of E2 glycoprotein. Further analysis would be required to assess if a similar 530 
defect is observed in the HCVcc system, although this is unlikely to be the case at 531 
least with the JFH-1W420V mutant, which exhibited infectivity levels that were similar 532 
to those of the wild type HCVcc (Fig. 1d).  533 
 534 
At first glance, a comparison of the data for binding and for neutralization by the E2 535 
conformational antibody HmAb CBH-5 or by sCD81-LEL shows a lack of direct 536 
correlation between the two properties. This is in concordance with observations in 537 
other virus systems, as neutralization activity is dependent on many additional factors 538 
(65-67). Our assays showed that the mutant E2 glycoproteins bound more weakly than 539 
the wild type to HmAb CBH-5 or sCD81-LEL, whereas the corresponding mutant 540 
virions were more sensitive than wild type virus to neutralization by these same 541 
molecules suggesting a clear difference between the wild type and mutant virions. 542 
There are numerous possible mechanisms that may influence sensitivity to 543 
neutralization. These include differences in binding affinity between wild type and 544 
mutant E2, the number of functional E1E2 complexes present on the virion surface 545 
and the number of antibody or receptor molecules required to neutralize. For example 546 
 23
a change in angle of the antibody relative to the virion surface will affect the amount 547 
of steric hindrance caused by a single molecule.  The HCV virion is protected by a 548 
glycan shield (68), therefore it is possible that mutation of W420 affects the position 549 
of the glycans and increases exposure of the antibody epitope. However, in the core 550 
E2 structure, the majority of glycans were positioned on a different face of E2 and the 551 
CD81/CBH-5 binding site was relatively exposed, suggesting that this is not a likely 552 
explanation (35). There is evidence that this region is masked by HVR1 (69-71) in the 553 
native virions. During virus entry interaction with a host factor induces a 554 
conformational change exposing the CD81-binding site and enabling interaction with 555 
CD81. Both wild type and mutant viruses were similarly neutralized by anti-CD81, 556 
which prevents virion-CD81 interaction by blocking CD81 receptors on the cell, 557 
indicating that substitution at position 420 did not alter CD81-dependence of 558 
infectivity. This demonstrates that there was no significant net decrease in virion-559 
CD81 interaction despite the decreased affinity for CD81, suggesting that this was 560 
counteracted by improved accessibility of the CD81-binding region. Indeed, the 561 
increased sensitivity to competition with sCD81-LEL indicates that the CD81-binding 562 
region on the mutant virion is more exposed than on the wild type virion. This 563 
observation is analogous to an earlier study of viruses with point mutations within this 564 
region. E1E2 containing the mutations N415D, T416A, N417S and I422L bound 565 
sCD81-LEL similarly or better than wild type (53). This is in contrast to E1E2 566 
containing mutations at position 420 that had reduced or undetectable levels of 567 
binding compared to wild type E1E2 supporting the hypothesis that tryptophan 420 is 568 
important for E2-CD81 interaction. The fact that the reduced affinity for E1E2 does 569 
not appear to have a detrimental effect on virion-CD81 interaction demonstrates either 570 
that increased exposure of CD81-binding sites on the virion can compensate 571 
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completely or that the affinity of E1E2 on the virion is not as strongly reduced by 572 
mutations at this position. 573 
 574 
The neutralization experiment with anti-SR-BI found that substitution of W420 575 
reduced the requirement for SR-BI for infectivity of these viruses. Again, this is 576 
consistent with several studies of viruses with mutations within this region. Viruses 577 
containing the point mutations I414T, N415D, T416A, N417S and I422L in E2 were 578 
all shown to have reduced sensitivity to inhibition by anti-SR-BI (53, 72). The HVR1 579 
region of E2 lies immediately upstream and virus with a complete deletion of HVR1 580 
(delHVR1) was shown to be completely resistant to neutralization by anti-SR-BI (69). 581 
The delHVR1 result was expected as several studies have shown that E2-SR-BI 582 
interaction maps to HVR1 and more recently that inhibition by anti-SR-BI or SR-BI 583 
inhibitors maps to this region (19, 69, 70). However, HVR1 is still present in the 584 
W420 mutants suggesting that the SR-BI binding site is less accessible in the mutant 585 
virions. The complete resistance of the W420 mutant viruses to the inhibitor BLT-4 586 
indicates that the reduced dependence on SR-BI is linked to the lipid transfer function 587 
which is required for both the access and enhancement functions of SR-BI. This is 588 
consistent with previous observations of mutant viruses N415D, T416A, N417S and 589 
I422L that were resistant to HDL-mediated enhancement, which requires the SR-BI 590 
lipid transfer activity (53, 73, 74). The observation that substitution of tryptophan 420 591 
also rendered the viruses resistant to erlotinib that targets EGFR and GAK, two 592 
components required for EGFR internalization suggests that the 420 mutant viruses do 593 
not use this route for entry. The reduced dependence on SR-BI together with the 594 
observation by Diao et al that erlotinib can also block SR-BI dependent HDL-595 
mediated enhancement strongly suggests that SR-BI, EGFR and GAK are involved in 596 
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the same entry route. The small but significant increase in sensitivity to sunitinib 597 
indicates that substitution at position 420 makes the virus more reliant on AAK1-598 
dependent internalization. Therefore, together with the CD81 data, this indicates a 599 
model where alteration at position 420 causes a subtle change in conformation or 600 
flexibility of HVR1 that prevents interaction with SR-BI and increases accessibility to 601 
the CD81 binding site. This in turn alters the entry requirements for clathrin-mediated 602 
uptake blocking the SR-BI, EGFR, GAK pathway and favoring the CD81, EGFR, 603 
AAK-1 route. 604 
 605 
Two of the antibodies tested (AP33 and 3/11) bind to E2412-423 and W420 has been 606 
identified as a critical binding residue for both antibodies by alanine scanning and 607 
structural analysis of antibody bound to peptide (34, 37-39). E2412-423 is structurally 608 
flexible and is recognized by each antibody in a different conformation. It adopts a β-609 
hairpin conformation when bound to mAb AP33 and a completely different linear, 610 
open conformation when bound to mAb 3/11. Our data suggest that W420 is less 611 
critical for interaction with mAb 3/11 as both hydrophobic substitutions retained 612 
binding activity for mAb 3/11. Scrutiny of the antigen/antibody interfaces reveals that 613 
the interaction of the W420 side chain with both antibodies is dominated 1) by 614 
hydrophobic interactions and 2) by hydrogen bonds of the NE1 atom with the 615 
carbonyl oxygens of T96 and T97 (mAb 3/11) or N91 (mAb AP33) of the light chain 616 
(Fig. 8). The spatial organization of the two antigen/antibody complexes is such that 617 
the distance between a hydrophobic phenyl ring as part of a phenylalanine or tyrosine 618 
side chain in position 420 and the respective carbonyl oxygens would be shorter for 619 
the AP33 complex  (~2.7Å) than for the 3/11 complex (~3.2Å). This disadvantageous 620 
interaction could explain the observed lower tolerance of mAb AP33 for a 621 
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phenylalanine or tyrosine residue at this position. Nevertheless, a hydrophobic residue 622 
at this position is essential as all other mutations ablated binding activity.  623 
 624 
Inspection of the neutralization profile of sCD81-LEL shows that JFH-1W420F virus is 625 
more sensitive to neutralization than JFH-1W420Y, suggesting that the hydroxyl group 626 
of the tyrosine side chain does not favor interaction with CD81. This is in line with 627 
the fact that only the JFH-1W420F mutant and not the JFH-1W420Y mutant partially 628 
retained CD81 binding activity and suggests that a polar group within the side chain 629 
of residue 420 is not beneficial for receptor binding. One possible interpretation of 630 
these results could be that this residue provides an additional hydrophobic anchor 631 
point to bind the mostly hydrophobic binding site within CD81 (75). Of note, a 632 
second antigenic region contributing to the CD81 binding site displays a hydrophobic 633 
protrusion constituted by F442 and Y443 that is essential for virus propagation (76). 634 
In conjunction with the conformational flexibility around W420 and the essential role 635 
of a hydrophobic side chain at position 420 this suggests a stabilizing role of W420 in 636 
E2-CD81 binding.  637 
 638 
The aim of the present study was to determine if the E2 residue W420 was indeed a 639 
contact residue for the CD81 receptor during HCVcc entry. Our results clearly show 640 
that W420 is required for virus entry and is required for E2-CD81 binding in the 641 
virion. In addition, our data highlights the relationship between E2-CD81 and E2-SR-642 
BI interaction as mutation at this position also modulates the interaction of the virion 643 
with the SR-BI receptor and the subsequent internalization route. The strong 644 
requirement for a hydrophobic residue at position 420 also provides new insights into 645 
the mode of binding to the cellular receptor. 646 
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FIGURE LEGENDS 939 
Figure 1. Analysis of W420 mutant viruses. Huh7 cells were transfected with viral 940 
RNA transcribed from cDNA encoding JFH-1WT, JFH-1GND, JFH-1DE1E2 and a panel 941 
of JFH-1W420 mutants and analyzed after 72h. (a) Intracellular viral replication was 942 
quantified by SEAP activity (RLU). (b) Viral titers were quantified by FFU/ml assay; 943 
black bars show extracellular virus harvested from the medium, grey bars show 944 
intracellular virus harvested from lysed cells. (c) Western blot analysis to detect (i) 945 
viral proteins Core, E2, NS5A and tubulin loading control in mock-infected (MI) and 946 
infected cell lysates and (ii) Core protein in released virus pelleted from infected cell 947 
supernatant. The blots shown are representative. (d) Released viral titers were 948 
quantified by FFU/ml assay from cells transfected with viral RNA transcribed from 949 
cDNA for JFH-1WT, JFH-1W420A and JFH-1W420V. Panels a, b and d show average 950 
values from duplicate independent experiments, error bars show SEM. 951 
 952 
Figure 2. Analysis of W420 mutants in the pseudoparticle system.  953 
Pseudoparticles were harvested from HEK cells transfected with wild type (WT), 420 954 
mutant E1E2 or no envelope (NE). (a) HCVpp infectivity in Huh7 cells is expressed 955 
as a percentage relative to wild type. The result shown is the average of 3 independent 956 
experiments, error bars show SEM. (b) Representative western blot of pelleted wild 957 
type and mutant HCVpp probed with anti-HCV E2 and anti-MLV Gag. 958 
 959 
Figure 3. Binding of E2 antibodies.  Reactivity of anti-E2 linear (a, b and c) and 960 
conformational (d) antibodies with lysate from cells expressing wild type and mutant 961 
E1E2 in GNA-ELISA. Bound antibodies were detected using secondary anti-species 962 
antibodies conjugated to HRP. Background levels were removed by subtracting 963 
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binding of a lysate lacking E1E2. Each dataset shows the average of 3 independent 964 
experiments, error bars show SEM.  965 
 966 
Figure 4. Neutralization by E2 antibodies. JFH-1WT, JFH-1W420F and JFH-1W420Y 967 
viruses were neutralized by mAb AP33 and mAb 3/11 that bind to E2412-423 (a and b) 968 
and by HmAb CBH-5 that binds immunodomain B (c). Each dataset shows the 969 
average of 2 independent experiments, error bars show SEM. 970 
 971 
Figure 5. Virus-CD81 receptor interactions. (a) Reactivity of sCD81-LEL in a 972 
modified GNA-ELISA with the same panel of WT and mutant E1E2-containing 973 
lysates as used in Fig. 3. Neutralization of JFH-1WT, JFH-1W420F and JFH-1W420Y 974 
viruses by (b) anti-CD81 and (c) sCD81-LEL. Each dataset shows the average of 2 975 
(b,c,d) or 3 (a) independent experiments, error bars show SEM. 976 
 977 
Figure 6. Virus-SR-BI receptor interactions. Cell surface expression of the fusion 978 
protein SR-BI.GFP was measured by detection of eGFP by flow cytometry. (a) The 979 
filled grey peak represents CHO-SR-BI cells; the black line represents CHO-SR-980 
BI.GFP cells. Expression of human SR-BI was measured by comparing the binding of 981 
by anti-SR-BI Mab151-NP1 (black line) and an IgG1 isotype control (filled grey 982 
peak) to (b) CHO-K1, (c) CHO-hSR-BI and (d) CHO-hSR-BI.GFP cells. (e) 983 
Neutralization of JFH-1WT, JFH-1W420F and JFH-1W420Y viruses by anti-SR-BI 984 
Mab151-NP1. A dose-response curve of BLT-4 on (f) infectivity of JFH-1WT, JFH-985 
1W420F and JFH-1W420Y viruses and (g) cell viability. Each dataset shows the average of 986 
2 (e) or 3 (f, g) independent experiments, error bars show SEM. 987 
 988 
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Figure 7: Virus-EGFR interactions. Dose-response curves for infectivity of JFH-989 
1WT, JFH-1W420F and JFH-1W420Y viruses in the presence of (a) erlotinib, (c) anti-EGFR 990 
and (d, e) sunitinib. For panel (e) wild type and 420 mutant viruses were analyzed by 991 
student t-test, asterisks show statistically significant differences (* = P<0.05, ** = 992 
P<0.05). The dose-response analysis of cell viability is shown for (b) erlotinib and (f) 993 
sunitinib. Each dataset shows the average of 2 (c) or 3 (a,b,d,e,f) independent 994 
experiments, error bars show SEM.  995 
 996 
Figure 8: Antibody-peptide interfaces. Detailed view of the interface between the 997 
common part of a synthetic E2 peptide (aa 413-423) with Fabs AP33 (left) and 3/11 998 
(right), respectively. The Fab is colored according to a normalized hydrophobicity 999 
scale from white (hydrophobic) to orange (hydrophilic). The hydrogen bonds 1000 
to carbonyl groups of residues NL91 (AP33) and TL96/TL97 (3/11) are shown as 1001 
dashed black lines, these carbonyl groups are shown as sticks and colored in red. 1002 
 1003 
 Figure 1. Analysis of W420 mutant viruses. Huh7 cells were transfected 
with viral RNA transcribed from cDNA encoding JFH-1WT, JFH-1GND, JFH-
1DE1E2 and a panel of JFH-1W420 mutants and analyzed after 72h. (a) 
Intracellular viral replication was quantified by SEAP activity (RLU). (b) 
Viral titers were quantified by FFU/ml assay; black bars show extracellular 
virus harvested from the medium, grey bars show intracellular virus 
harvested from lysed cells. (c) Western blot analysis to detect (i) viral 
proteins Core, E2, NS5A and tubulin loading control in mock-infected (MI) 
and infected cell lysates and (ii) Core protein in released virus pelleted from 
infected cell supernatant. The blots shown are representative. (d) Released 
viral titers were quantified by FFU/ml assay from cells transfected with viral 
RNA transcribed from cDNA for JFH-1WT, JFH-1W420A and JFH-1W420V. 
Panels a, b and d show average values from duplicate independent 
experiments, error bars show SEM. 
  
Figure 2. Analysis of W420 mutants in the pseudoparticle system.  
Pseudoparticles were harvested from HEK cells transfected with wild 
type (WT), 420 mutant E1E2 or no envelope (NE). (a) HCVpp 
infectivity in Huh7 cells is expressed as a percentage relative to wild 
type. The result shown is the average of 3 independent experiments, 
error bars show SEM. (b) Representative western blot of pelleted wild 
type and mutant HCVpp probed with anti-HCV E2 and anti-MLV Gag. 
 Figure 3. Binding of E2 antibodies.  Reactivity of anti-E2 linear (a, b and c) 
and conformational (d) antibodies with lysate from cells expressing wild type 
and mutant E1E2 in GNA-ELISA. Bound antibodies were detected using 
secondary anti-species antibodies conjugated to HRP. Background levels were 
removed by subtracting binding of a lysate lacking E1E2. Each dataset shows 
the average of 3 independent experiments, error bars show SEM.  
 
  
Figure 4. Neutralization by E2 antibodies. JFH-1WT, JFH-1W420F and JFH-1W420Y viruses were neutralized by mAb AP33 and mAb 3/11 that 
bind to E2412-423 (a and b) and by HmAb CBH-5 that binds immunodomain B (c). Each dataset shows the average of 2 independent experiments, 
error bars show SEM. 
 
 Figure 5. Virus-CD81 receptor interactions. (a) Reactivity of sCD81-LEL in a modified GNA-ELISA with the same panel of WT and mutant 
E1E2-containing lysates as used in Fig. 3. Neutralization of JFH-1WT, JFH-1W420F and JFH-1W420Y viruses by (b) anti-CD81 and (c) sCD81-LEL. 
Each dataset shows the average of 2 (b,c,d) or 3 (a) independent experiments, error bars show SEM. 
 Figure 6. Virus-SR-BI receptor interactions. Cell surface expression of the fusion protein 
SR-BI.GFP was measured by detection of eGFP by flow cytometry. (a) The filled grey peak 
represents CHO-SR-BI cells; the black line represents CHO-SR-BI.GFP cells. Expression of 
human SR-BI was measured by comparing the binding of by anti-SR-BI Mab151-NP1 (black 
line) and an IgG1 isotype control (filled grey peak) to (b) CHO-K1, (c) CHO-hSR-BI and (d) 
CHO-hSR-BI.GFP cells. (e) Neutralization of JFH-1WT, JFH-1W420F and JFH-1W420Y viruses 
by anti-SR-BI Mab151-NP1. A dose-response curve of BLT-4 on (f) infectivity of JFH-1WT, 
JFH-1W420F and JFH-1W420Y viruses and (g) cell viability. Each dataset shows the average of 2 
(e) or 3 (f, g) independent experiments, error bars show SEM. 
 Figure 7: Virus-EGFR interactions. Dose-response curves for infectivity of JFH-1WT, JFH-1W420F and JFH-1W420Y 
viruses in the presence of (a) erlotinib, (c) anti-EGFR and (d, e) sunitinib. For panel (e) wild type and 420 mutant 
viruses were analyzed by student t-test, asterisks show statistically significant differences (* = P<0.05, ** = P<0.05). 
The dose-response analysis of cell viability is shown for (b) erlotinib and (f) sunitinib. Each dataset shows the 
average of 2 (c) or 3 (a,b,d,e,f) independent experiments, error bars show SEM.  
  
 
 
 
Figure 8. Antibody-peptide interfaces. Detailed view of the interface between the common 
part of a synthetic E2 peptide (aa 413-423) with Fabs AP33 (left) and 3/11 (right), 
respectively. The Fab is colored according to a normalized hydrophobicity scale from white 
(hydrophobic) to orange (hydrophilic). The hydrogen bonds to carbonyl groups of residues 
NL91 (AP33) and TL96/TL97 (3/11) are shown as dashed black lines, these carbonyl groups 
are shown as sticks and colored in red. 
